ALLO vs. IOVA, PRAX, GLPG, WVE, APGE, EVO, IRON, ARQT, AMPH, and IMCR
Should you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Iovance Biotherapeutics (IOVA), Praxis Precision Medicines (PRAX), Galapagos (GLPG), Wave Life Sciences (WVE), Apogee Therapeutics (APGE), Evotec (EVO), Disc Medicine (IRON), Arcutis Biotherapeutics (ARQT), Amphastar Pharmaceuticals (AMPH), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry.
Allogene Therapeutics vs.
Iovance Biotherapeutics (NASDAQ:IOVA) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.
Allogene Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -451.25%. Allogene Therapeutics' return on equity of -52.13% beat Iovance Biotherapeutics' return on equity.
In the previous week, Allogene Therapeutics had 2 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 8 mentions for Allogene Therapeutics and 6 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.65 beat Allogene Therapeutics' score of 0.40 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.
Iovance Biotherapeutics presently has a consensus target price of $21.07, suggesting a potential upside of 264.56%. Allogene Therapeutics has a consensus target price of $9.73, suggesting a potential upside of 348.54%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Iovance Biotherapeutics.
Iovance Biotherapeutics received 285 more outperform votes than Allogene Therapeutics when rated by MarketBeat users. Likewise, 74.34% of users gave Iovance Biotherapeutics an outperform vote while only 65.57% of users gave Allogene Therapeutics an outperform vote.
Allogene Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 12.1% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 24.3% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Iovance Biotherapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.
Summary
Allogene Therapeutics beats Iovance Biotherapeutics on 13 of the 18 factors compared between the two stocks.
Get Allogene Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allogene Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALLO) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ALLO Stock Alerts